Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Nicholas Miltgen"'
Autor:
Amanda C. Winters, Mohd Minhajuddin, Brett M. Stevens, Ajay Major, Grace Bosma, Diana Abbott, Nicholas Miltgen, Ji Yuan, Amy L. Treece, Bradford J. Siegele, Mark D. Ewalt, Jonathan A. Gutman, Craig T. Jordan, Daniel A. Pollyea
Publikováno v:
Haematologica, Vol 109, Iss 6 (2023)
Venetoclax with azacitidine (ven/aza) is a lower-intensity therapeutic regimen that has been shown to improve outcomes in elderly patients with acute myeloid leukemia (AML). Measurable residual disease (MRD) using flow cytometry is a valuable tool fo
Externí odkaz:
https://doaj.org/article/dd1f3941b21d43f7a99618a3961ccd30
Autor:
Zohra Nooruddin, Nicholas Miltgen, Qi Wei, Jeffrey Schowinsky, Zengang Pan, Jennifer Tobin, Enkhtsetseg Purev, Jonathan A. Gutman, William Robinson, Daniel A. Pollyea
Publikováno v:
Haematologica, Vol 102, Iss 5 (2017)
Externí odkaz:
https://doaj.org/article/624e7a2fb95846ce87cd86cbb4a8ed86
Autor:
Mohd Minhajuddin, Brett M. Stevens, Ajay Major, Nicholas Miltgen, Ji Yuan, Amy Treece, Jonathan A. Gutman, Craig T Jordan, Daniel A. Pollyea
Publikováno v:
Blood. 140:6274-6275
Autor:
Shireen Vali, Diana Abbott, Andrew Hammes, Derek Schatz, Gregory Hemenway, Neeraj Kumar Singh, Clayton A. Smith, Taher Abbasi, Brett M. Stevens, Jonathan A. Gutman, Daniel A. Pollyea, Craig T. Jordan, Christopher R. Cogle, Aaron Fullerton, Amanda Winters, Nicholas Miltgen, Qi Wei, Leylah Drusbosky
Publikováno v:
Leukemia Research. 81:43-49
Background Patients with relapsed and refractory (R/R) acute myeloid leukemia (AML) have limited treatment options. Genomically-defined personalized therapies are only applicable for a minority of patients. Therapies without identifiable targets can
Autor:
Nicholas Miltgen, Jeffrey Schowinsky, Qi Wei, Zohra Nooruddin, Enkhtsetseg Purev, Daniel A. Pollyea, Zengang Pan, William A. Robinson, Jennifer Tobin, Jonathan A. Gutman
In 2008, the World Health Organization (WHO) recognized the BCR-ABL1 negative myeloproliferative neoplasm (MPN) chronic neutrophilic leukemia (CNL) as a distinct entity based on the features of an increased white blood cell count (WBC) with a prepond
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eec1f219bb11043795f07e5e476a2b01
https://europepmc.org/articles/PMC5477626/
https://europepmc.org/articles/PMC5477626/